The arrival of Retatrutide ZPHC, at a concentration of 120mg, is sparking considerable buzz within the healthcare community. This groundbreaking dual GIP and GLP-1 target medication appears to offer significant improvements in weight reduction compared to existing therapies. Preliminary clinical